RxDoctor Payments Data

David James, MD

Interventional Cardiology · Cedar Knolls, NJNPI 1205093846

Payments from drug & device makers

$10,850in general payments, 2019–2025

Across 590 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • Novartis$1K
  • Boston Scientific$897
  • AstraZeneca$781
  • Merck$604
  • Johnson & Johnson$551
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$10,805100%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,850 in reported general payments places this provider in the 55th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$983,725
Medicare patients
1,591
Services billed
11,540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis51$1,124,765
EliquisApixaban619$699,731
XareltoRivaroxaban208$214,599
JardianceEmpagliflozin161$205,723
EntrestoSacubitril/Valsartan84$118,306
MultaqDronedarone Hcl71$106,625
Repatha SureclickEvolocumab104$106,620
FarxigaDapagliflozin Propanediol94$92,608
MounjaroTirzepatide35$48,855
BrilintaTicagrelor36$37,758
VerquvoVericiguat11$20,518
Icosapent Ethyl39$16,143
OzempicSemaglutide14$12,943
NexletolBempedoic Acid16$11,472
Metoprolol Succinate722$11,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$308$1,824,497670 claims
Johnson & JohnsonXarelto$551$214,599208 claims
Boehringer IngelheimJardiance$1,233$205,723161 claims
AstraZenecaFarxiga, Brilinta$781$130,366130 claims
NovartisEntresto$1,016$118,30684 claims
Sanofi-aventis U.S. LLCMultaq$404$106,62571 claims
Lilly USA, LLCMounjaro$84$48,85535 claims
MerckVerquvo$604$20,51811 claims
Novo NordiskOzempic$490$12,94314 claims
Esperion Therapeutics, Inc.Nexletol$282$11,47216 claims
Arbor Pharmaceuticals, Inc.Edarbi$127$5,80913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in Cedar Knolls

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →